Parkinson's UK

MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.

Lucy Therapeutics is a biotech company focused on developing innovative treatments for neurological diseases that originate from mitochondrial dysfunction. The company utilizes a unique approach to drug discovery by targeting early disease mechanisms, which holds potential for addressing a range of neurological disorders, including Parkinson's Disease and Alzheimer's Disease. In addition to its therapeutic efforts, Lucy Therapeutics is engaged in the development of proprietary small molecule therapies and diagnostic biomarkers aimed at enhancing the understanding and treatment of central nervous system conditions. By leveraging genetic technologies, the company aims to provide deeper insights into personalized medicine, thereby improving patient outcomes and enabling more precise healthcare interventions in the neurological field.

Neumora Therapeutics is a clinical-stage biotechnology company focused on developing precision medicines for brain diseases by combining data science with neuroscience. Founded to address the global brain disease crisis, Neumora takes an innovative approach to treatment development. The company has established a robust therapeutic pipeline that includes seven clinical and preclinical neuroscience programs targeting novel mechanisms of action for various underserved neuropsychiatric and neurodegenerative disorders. Neumora plans to advance its pipeline further by initiating multiple clinical trials across its programs in the upcoming 12 to 18 months.

The University of Nottingham is a prominent institution known for its comprehensive and research-led approach to education. It operates an international business school with campuses in the UK, China, and Malaysia, emphasizing strong ties to the corporate sector and delivering high-quality teaching programs. The business school is recognized for its influential research, particularly in areas such as banking and finance, entrepreneurship, innovation, and business sustainability. The university is financially secure and committed to enhancing the international experience for its students, preparing them for diverse intellectual, professional, and personal endeavors. Additionally, the University manages an endowment fund that supports scholarships, academic positions, and various research and public service initiatives.

NRG Therapeutics is a drug discovery company established in 2018 that specializes in developing therapeutic approaches aimed at restoring mitochondrial function to address neurodegenerative diseases, including Parkinson’s disease, Alzheimer’s disease, and motor neuron disease. The company focuses on creating novel medicines that preserve mitochondrial function and halt disease progression. With a team experienced in neuroscience drug discovery, NRG Therapeutics is initially concentrating on the discovery and development of brain-penetrant inhibitors of the mitochondrial permeability transition pore specifically for Parkinson’s disease. This strategic focus is intended to empower physicians with effective treatment options for patients suffering from chronic neurodegenerative disorders.

NRG Therapeutics is a drug discovery company established in 2018 that specializes in developing therapeutic approaches aimed at restoring mitochondrial function to address neurodegenerative diseases, including Parkinson’s disease, Alzheimer’s disease, and motor neuron disease. The company focuses on creating novel medicines that preserve mitochondrial function and halt disease progression. With a team experienced in neuroscience drug discovery, NRG Therapeutics is initially concentrating on the discovery and development of brain-penetrant inhibitors of the mitochondrial permeability transition pore specifically for Parkinson’s disease. This strategic focus is intended to empower physicians with effective treatment options for patients suffering from chronic neurodegenerative disorders.

Keapstone Therapeutics Limited is a biotechnology company based in Sheffield, United Kingdom, focused on drug development targeting the Nrf2 signaling pathway for conditions such as Parkinson's disease and Motor Neuron Disease (MND). Founded in 2017, the company specializes in developing a novel series of small molecule activators that prevent the interaction between KEAP1 and Nrf2. This mechanism enhances redox balance, improves mitochondrial function, promotes autophagy, and reduces inflammation, ultimately aiming to improve the quality of life for individuals suffering from Parkinson's disease. In addition to its drug development efforts, Keapstone Therapeutics engages in biotechnology research and offers consulting services related to fatal neurodegenerative diseases.